PUBLISHER: TechNavio | PRODUCT CODE: 1524911
PUBLISHER: TechNavio | PRODUCT CODE: 1524911
The gastrointestinal diseases therapeutics market is forecasted to grow by USD 18526.1 mn during 2023-2028, accelerating at a CAGR of 6.81% during the forecast period. The report on the gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of gastrointestinal diseases, new gastrointestinal therapeutics product launches, and increasing demand for biologics and targeted therapies.
Technavio's gastrointestinal diseases therapeutics market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 6.26% |
CAGR | 6.81% |
Incremental Value | $18526.1mn |
By Drug Class
By Type
By Geographical Landscape
This study identifies the availability of nutritional therapies as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years. Also, emergence of microbiome-based therapies and increase in self-medication coupled with home-based therapies will lead to sizable demand in the market.
The report on the gastrointestinal diseases therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastrointestinal diseases therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and UCB SA. Also, the gastrointestinal diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Exhibits: